Participated · Series B · Dec 2021

Babyscripts offers a mobile clinical solution for remote monitoring in pregnancy, combining a mobile app with internet-connected devices, digital education, and customized risk-specific experiences. The platform enables providers and payers to manage patients via risk-based care modules, remote monitoring, and automated care elements. Babyscripts reports managing more than 200K unique pregnancies across 30 states and says its tools can allow providers to manage up to 90% of pregnancies virtually. The solution is delivered via a joint deployment model that incorporates payers sponsoring platform use at participating sites to identify and triage member risk and improve care coordination. The company emphasizes targeting and reducing systemic racial and ethnic inequities in maternal and infant outcomes. Babyscripts intends to use the new funding to accelerate rollout of its Virtual Maternity Care solution across U.S. providers and to develop models specifically designed for payers; the company has raised $37M to date. Babyscripts offers a virtual maternity care platform that pairs medical-device kits (blood pressure, weight, captured blood sugars) with a mobile app to monitor and alert clinicians to maternal health issues. The platform can automate roughly 40%–50% of prenatal care and has been shown to accelerate diagnoses (for example, preeclampsia detected 13 days faster than standard care at a site). Babyscripts is used by 75 health systems across 32 states and monitors about 250,000 women annually; more than 70% of its patients are on Medicaid. The company expanded product lines from a single device to multiple targeted kits and recently launched a mental health product while developing a substance use disorder experience. Babyscripts has formed partnerships with public health departments, managed Medicaid plans and providers to enable local payment and broader deployment. The company grew enrollments 10x during the pandemic and has 45 employees, with plans to double headcount in the next 12–18 months to support product, payer growth, clinical expertise, implementation and customer success. Babyscripts builds a clinically validated virtual care platform that allows OBGYNs to deliver a new model of prenatal and postpartum care using internet-connected devices for remote monitoring. The platform offers risk-specific experiences and the company says it can allow providers to manage up to 90% of pregnancies virtually. Babyscripts has spent six years developing what it describes as the most-implemented mobile clinical solution for remote monitoring in pregnancy and was named to CB Insights' 2020 Digital Health 150. The company emphasizes partnering with physicians and health systems to guide product development and improve maternal outcomes. Its stated mission is to eliminate maternal mortality and expand access to care. Recent health-system partnerships are intended to align Babyscripts' roadmap with customer needs and support scaling of its virtual maternity care solutions. Babyscripts offers a clinically-validated virtual care obstetrics platform that uses internet-connected devices for remote monitoring to support prenatal and postpartum care. The core product delivers risk-specific experiences to allow OBGYNs to manage a large portion of pregnancies remotely. The system is designed to detect risk more quickly and automate elements of care, enabling providers to manage up to 90% of pregnancies virtually. Led by CEO and co-founder Anish Sebastian, the company has spent the last four years building this platform. Babyscripts recently acquired iBirth, expanding its offering to include a provider-delivered, co-branded pregnancy app and a more holistic pregnancy and postpartum program. Financially, Babyscripts raised $500K from Inova Health System, which will support deployment of the platform. Babyscripts develops a mobile app and remote-monitoring devices that track blood pressure and weight and deliver neonatal care information to expecting mothers. The company works with hospitals and healthcare providers to distribute its devices and software, creating a channel between patients and OBGYNs throughout pregnancy. Using remote monitoring, Babyscripts says it can tailor treatments to risk profiles and enable providers to manage up to 90% of pregnancies virtually. The platform is already being used to monitor 160,000 pregnancies across 20 states, and the company reports average patient engagement of six app or monitoring interactions per week. Leadership says the company will use funding to continue acquiring market share and build additional products for pregnancy patients, including postpartum and early-stage pediatric services through expanded offerings.

Led · Equity · Sep 2013

Orca Pharmaceuticals was spun out by BioMotiv in partnership with New York University to develop therapeutics for inflammatory diseases. The company is pursuing orally administered small‑molecule inhibitors of the nuclear hormone receptor RORyt, which the scientific founders say controls activation of T cells that produce interleukin‑17. Orca plans to develop treatments for psoriasis, ankylosing spondylitis and inflammatory bowel disease, and is working toward proof of concept of an oral psoriasis therapeutic in 2016. The scientific founders are Prof. Dan Littman and Jun Huh of NYU; operational leadership and drug development are led by co‑founders Michael Hunter (CEO) and Roy Pettipher (CSO). Orca is located in Oxford, UK, and its board includes representatives from BioMotiv. The company was funded by BioMotiv and NYU’s Innovation Venture Fund, with SEC filings indicating investments totaling $800,000.

Participated · Equity · Sep 2012

BioMotiv is the for‑profit therapeutic accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative centered at University Hospitals in Cleveland. The company leverages an experienced team and advisory board to identify, select, fund, and actively manage a portfolio of physician‑scientist–derived programs sourced from research institutions and disease foundations. Its model focuses on advancing bench discoveries through proof of concept and into clinical development with the goal of eventual commercialization. As part of a new strategic partnership, Takeda has made an initial 25 oku‑yen ($25M USD) investment in BioMotiv payable over five years and obtained exclusive rights to programs BioMotiv sources in Immunology & Inflammation and cardio‑metabolic diseases. BioMotiv says the partnership is intended to provide a seamless continuum of expertise to accelerate development of physician‑scientist innovations. The arrangement links BioMotiv’s accelerator model with Takeda’s pharmaceutical capabilities to push prioritized programs toward clinical development and commercialization. BioMotiv is a Cleveland, OK-based for-profit therapeutic accelerator affiliated with The Harrington Project for Discovery and Development. Led by CEO Baiju R. Shah, the company sources a technology portfolio from leading academic medical centers and industry sources across the country. The company intends to use its recent funding to launch operations and initiate development of that portfolio. BioMotiv raised $21M from founding investors University Hospitals and the Harrington Family. The Harrington Project is a $250M initiative announced by University Hospitals in February. BioMotiv plans to raise a total of $100M in capital.